← Back to Patent Explorer
US4002731A Expired / Lapsed US ⏱️ 0.0 years remaining

Diagnostic process using sodium tyropanoate

Assignee: STWB Inc
•
Filing: 1974-06-17
•
Granted: 1977-01-11
•
Expires: 1994-06-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Divided doses or sustained release formulations of sodium tyropanoate upon oral administration provide adequate gallbladder visualization with substantially lower blood levels than are obtained with conventional single dose administration.

Inventors

  • 👤 Thomas W. Skulan

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 06:10
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/04; A61K49/0433; A61K49/0447; A61K49/0495; A61K9/00; A61K9/48; A61K9/50; A61K9/5005; A61K9/5015; A61K9/5021; A61K9/5036; A61K9/5042; A61K9/5047; A61K9/5084

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 111 words
A process which comprises administering orally to a mammal possessing a gallbladder, a single undivided dose in a sustained or controlled release formulation or intermittently over a period of between about four and about ten hours, an amount of sodium tyropanoate of between about 25 and 100 milligrams per kilogram of body weight of the mammal, whereby a concentration of iodine in the gallbladder sufficient to provide adequate X-ray visualization of the gallbladder is obtained, while maintaining the maximum iodine concentration in the blood significantly lower than the maximum iodine concentration in the blood obtained by oral administration of an initial single dose of the same total amount of sodium tyropanoate.
Claim 2
Dependent Claim 111 words
A process which comprises administering orally to a mammal possessing a gallbladder, a single undivided dose in a sustained or controlled release formulation or intermittently over a period of between about four and about ten hours, an amount of sodium tyropanoate of between about 25 and 100 milligrams per kilogram of body weight of the mammal, whereby a concentration of iodine in the gallbladder sufficient to provide adequate X-ray visualization of the gallbladder is obtained, while maintaining the maximum iodine concentration in the blood significantly lower than the maximum iodine concentration in the blood obtained by oral administration of an initial single dose of the same total amount of sodium tyropanoate.
Claim 3
Dependent Claim 35 words
The process according to claim 1 in which the sodium tyropanoate is administered in from three to six approximately equally divided doses at approximately equal intervals over a period of between 4 and 10 hours.
Claim 4
Dependent Claim 87 words
A process which comprises administering orally to a mammal possessing a gallbladder a sustained release formulation comprising an amount of sodium tyropanoate of between about 25 and 100 milligrams per kilogram of body weight of the mammal, whereby a concentration of iodine in the gallbladder sufficient to provide adequate X-ray visualization of the gallbladder is obtained while maintaining the maximum iodine concentration in the blood significantly lower than the maximum iodine concentration in the blood obtained by oral administration of the same amount of sodium tyropanoate alone.
Claim 5
Dependent Claim 87 words
A process which comprises administering orally to a mammal possessing a gallbladder a sustained release formulation comprising an amount of sodium tyropanoate of between about 25 and 100 milligrams per kilogram of body weight of the mammal, whereby a concentration of iodine in the gallbladder sufficient to provide adequate X-ray visualization of the gallbladder is obtained while maintaining the maximum iodine concentration in the blood significantly lower than the maximum iodine concentration in the blood obtained by oral administration of the same amount of sodium tyropanoate alone.

References Cited (Backward Citations)

US1815902A Cited
US2436270A Cited
US2801203A Cited
US2790748A Cited
US2895988A Cited
US3184386A Cited
US3144479A Cited
US3042715A Cited
US3226431A Cited
US3133863A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-01-11 1980-07-12 1981-01-11 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-01-11 1984-07-12 1985-01-11 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-01-11 1988-07-12 1989-01-11 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag